aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Merck & Co., Inc., based in Rahway, New Jersey, is a global healthcare company that operates through two main segments: Pharmaceutical and Animal Health. The Pharmaceutical segment focuses on human health products, including treatments for oncology, acute care, immunology, neuroscience, virology, cardiovascular diseases, and diabetes, as well as vaccines for various age groups. The Animal Health segment develops and markets veterinary pharmaceuticals and vaccines. Merck's mission is to discover, develop, and provide innovative products and services that save and improve lives around the world.
Notable figures associated with Merck include Friedrich Jacob Merck, the founder, and key leaders such as Belén Garijo. The company has achieved significant milestones in medical research and development, contributing to advancements in both human and animal health. Merck's impact is evident in its extensive portfolio of life-saving medications and vaccines, which have made substantial contributions to global health. The company continues to be a leader in the pharmaceutical industry, driven by its commitment to innovation and excellence.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Pharmaceuticals
Technology
Biotech
Tags
Healthtech
Model Types
Retail
Revenue Type(s)
Transactional
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Merck & CO INC Cedear EAC 5 RE founded?
Merck & CO INC Cedear EAC 5 RE was founded in 1891.
Where is Merck & CO INC Cedear EAC 5 RE’s headquarters located?
Merck & CO INC Cedear EAC 5 RE’s headquarters is located in Bogota, CO.
When was Merck & CO INC Cedear EAC 5 RE’s last funding round?
Merck & CO INC Cedear EAC 5 RE’s most recent funding round was for $2.6M (USD) in March 2023.
How many employees does Merck & CO INC Cedear EAC 5 RE have?
Merck & CO INC Cedear EAC 5 RE has 69000 employees as of Feb 6, 2024.
How much has Merck & CO INC Cedear EAC 5 RE raised to-date?
As of July 05, 2023, Merck & CO INC Cedear EAC 5 RE has raised a total of $8.2M (USD) since Mar 3, 2023.
Add Comparison
Total Raised to Date
$8.2M
USD
Last Update Mar 3, 2023
Last Deal Details
$2.6M
USD
Mar 3, 2023
Grant
Total Employees Over Time
69000
As of Feb 2024
Merck & CO INC Cedear EAC 5 RE Address
Bogota,
Bogotá
Colombia
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts